Clinical trials · California
Solid Tumor clinical trials in California
We’re tracking 333 recruiting solid tumor studies with a site in California — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT06108050RecruitingPhase 1
Testing a new drug alone and with pembrolizumab for advanced solid tumors
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Encinitas, CaliforniaAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06014502RecruitingPhase 1
Study of IMGS-001 for advanced solid tumors that returned after treatment
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Santa Monica, CaliforniaAges 18 years+ - NCT05981703RecruitingPhase 1
Study of BGB-26808 alone or with tislelizumab for advanced solid tumors
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05985161RecruitingPhase 2
Selinexor for wilms tumor and other solid tumors
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Los Angeles, CaliforniaAges 1 year+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05836324RecruitingPhase 1
Safety study of an anti-cancer drug for advanced tumors
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT05720117RecruitingPhase 1
Study drug for advanced solid tumors with limited treatments left
This Phase 1 study tests PYX-201 in people with advanced (grown or spread) solid cancers to see if it is safe and how it works. You may qualify if your cancer has had up to a couple of prior treatments and you can safely take study medicines and undergo required testing like a tumor biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Sacramento, CaliforniaAges 12 years+ - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Palo Alto, CaliforniaAges 12 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04913285RecruitingPhase 1
KIN-2787 for advanced solid tumors with BRAF or NRAS mutations
This trial tests a new drug, KIN-2787, for people with advanced solid tumors that have specific changes (mutations) in the BRAF or NRAS genes. The drug is designed to target these changes and may help shrink or control the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04665206RecruitingPhase 1/Phase 2
Testing VT3989 for certain advanced cancers
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
San Francisco, CaliforniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04219254RecruitingPhase 1/Phase 2
Testing BI-1206 with pembrolizumab for advanced solid cancers
This early-phase trial studies BI-1206 together with pembrolizumab to treat advanced solid tumors. It may be an option if your cancer has progressed after prior anti–PD-1/PD-L1 treatment (or, in some groups, if standard treatments aren’t suitable).
Los Angeles, CaliforniaAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT03093116RecruitingPhase 1/Phase 2
Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Duarte, CaliforniaAges 12 years+ - NCT05068583Recruiting
Testing liquid blood samples in children with certain cancers
This trial studies “liquid biopsies,” which are blood tests, to help learn about specific cancers in children. It may help doctors monitor cancer and guide treatment using less invasive tests.
Los Angeles, CaliforniaAges 6 months+
Solid Tumor trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting solid tumor studies listed above.
- City of Hope · 3 studies
- UCLA Jonsson Comprehensive Cancer Center · 3 studies
- UCSF Helen Diller Family Comprehensive Cancer Center · 3 studies
- University of California, Los Angeles (UCLA) · 3 studies
- Children's Hospital Los Angeles · 2 studies
- Sarcoma Oncology Center · 2 studies
- Stanford Cancer Institute · 2 studies
- University of California, Davis Comprehensive Cancer Center · 2 studies
What taking part in a solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Solid Tumor trials in other states
Common questions
- Are there solid tumor clinical trials in California?
- Yes. We're currently tracking 333 recruiting solid tumor studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.